EMG
ADAP

Ellington Management Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Ellington Management Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,000
Closed -$180K – 569
2017
Q3 		$180K Buy
+22,000
New +$137K 0.03% 541

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ellington Management Group's ADAP Position: Q4 2017 in Review

Ellington Management Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2017, closing a stake of 22,000 shares — an estimated $180K sold.

Ellington Management Group first reported a position in ADAP in Q3 2017 and held it in 1 quarter. The position peaked at $180K in Q3 2017. 71 funds tracked by Wall St. Rank hold ADAP as of Q4 2017.

  • Ellington Management Group reported no remaining Adaptimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 22,000 Adaptimmune Therapeutics shares in Q4 2017, an estimated $180K.
  • Ellington Management Group first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 1 quarter.
  • Ellington Management Group's Adaptimmune Therapeutics position peaked at $180K in Q3 2017.
  • 71 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.